RecruitingPhase 4NCT07135453

Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines

Novel Serotype Alert: Investigate New Pneumococcal Conjugate Vaccines for Inducing Cross-protection Against Newly Discovered Serotype 33E and Putative Novel Serogroup 33 Serotypes

Sponsor

University of Alabama at Birmingham

Enrollment

70 participants

Start Date

Jul 1, 2026

Study Type

INTERVENTIONAL

Conditions

Vaccine Pneumococcal disease

Summary

The goal of this study is to learn whether different types of vaccines to prevent bacterial infections are able to effectively create antibodies that defend against certain types of bacteria. We will give two different types of vaccine and evaluate the effectiveness of antibodies produced by each vaccine in killing bacteria.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Pneumococcal Vaccine for people with pneumococcal disease and vaccine. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.